Renovorx, Inc. ( (RNXT) ) has released its Q3 earnings. Here is a breakdown of the information Renovorx, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies and commercializing its FDA-cleared drug-delivery device, RenovoCath®, within the healthcare sector. The company aims to address unmet medical needs through innovative solutions.
In its third-quarter 2025 earnings report, RenovoRx highlighted a year-to-date revenue of approximately $900,000, reflecting the growing demand for its RenovoCath device. The company has expanded its reach to 14 cancer centers and is actively pursuing further growth through strategic hiring and market development.
Key financial metrics from the report include third-quarter revenues of $266,000, a cash position of $10 million, and a net loss of $2.9 million. The company is advancing its Phase III TIGeR-PaC trial, with enrollment expected to complete in early 2026, and has launched a post-marketing registry study to gather real-world evidence.
Looking ahead, RenovoRx is poised for revenue growth in 2026 as it continues to expand its commercial footprint and clinical trials. The management remains committed to strategic expansion and improving patient outcomes through its targeted therapy platform.